Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy

Summary

The study is designed to determine the 32 month rate of distant relapse in patients with uveal melanoma who are at high risk of recurrence following definitive therapy with surgery or radiation who receive adjuvant crizotinib; and secondarily, the overall survival and disease specific survival in this patient population.

Timeline

Start

2015-03

Primary completion

2019-07-03

Completion

2019-07-03

Drugs

Indications